Correction to: SentimagIC: A Non-inferiority Trial Comparing Superparamagnetic Iron Oxide Versus Technetium-99m and Blue Dye in the Detection of Axillary Sentinel Nodes in Patients with Early-Stage Breast Cancer (Annals of Surgical Oncology, (2019), 26, 11, (3510-3516), 10.1245/s10434-019-07577-4)

Michael D. Alvarado, Elizabeth A. Mittendorf, Mediget Teshome, Alastair M. Thompson, Richard J. Bold, Mark A. Gittleman, Peter D. Beitsch, Sarah L. Blair, Kaisa Kivilaid, Quentin J. Harmer, Kelly K. Hunt

Research output: Contribution to journalComment/debate

Abstract

In the original article the authors’ disclosures were incomplete. Following is the revised text: This clinical study was sponsored by Endomagnetics Inc., which provided funding to the institutions of all authors (K. Hunt PI). Dr. Michael D. Alvarado received travel support from Endomagnetics Inc. All other authors reported no conflicts of interest.

Original languageEnglish (US)
JournalAnnals of Surgical Oncology
DOIs
StateAccepted/In press - Jan 1 2020

ASJC Scopus subject areas

  • Surgery
  • Oncology

Fingerprint Dive into the research topics of 'Correction to: SentimagIC: A Non-inferiority Trial Comparing Superparamagnetic Iron Oxide Versus Technetium-99m and Blue Dye in the Detection of Axillary Sentinel Nodes in Patients with Early-Stage Breast Cancer (Annals of Surgical Oncology, (2019), 26, 11, (3510-3516), 10.1245/s10434-019-07577-4)'. Together they form a unique fingerprint.

  • Cite this